DNTH vs APLS vs RARE vs BEAM vs IONS

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -67. 3% for Dianthus Therapeutics, Inc. (DNTH). Apellis Pharmaceuticals, Inc. (APLS) offers the better valuation at 227. 9x trailing P/E, making it the more compelling value choice. Analysts rate Dianthus Therapeutics, Inc. (DNTH) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ionis Pharmaceuticals, Inc.

(IONS) delivered a total return of +94. 6%, compared to -76. 4% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: IONS returned +243. 8% versus DNTH's -67. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ionis Pharmaceuticals, Inc.

(IONS) is the lower-risk stock at 0. 41β versus Beam Therapeutics Inc. 's 2. 27β — meaning BEAM is approximately 452% more volatile than IONS relative to the S&P 500. On balance sheet safety, Dianthus Therapeutics, Inc. (DNTH) carries a lower debt/equity ratio of 0% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus -67. 3% for Dianthus Therapeutics, Inc. (DNTH). On earnings-per-share growth, the picture is similar: Apellis Pharmaceuticals, Inc. grew EPS 111. 3% year-over-year, compared to -64. 7% for Dianthus Therapeutics, Inc.. Over a 3-year CAGR, APLS leads at 137. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Apellis Pharmaceuticals, Inc.

(APLS) is the more profitable company, earning 2. 2% net margin versus -79. 7% for Dianthus Therapeutics, Inc. — meaning it keeps 2. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: APLS leads at 5. 5% versus -87. 4% for DNTH. At the gross margin level — before operating expenses — DNTH leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ionis Pharmaceuticals, Inc.

(IONS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +243. 8% 10Y return). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 27 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IONS: +243. 8%, BEAM: +56. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DNTH is a small-cap quality compounder stock; APLS is a small-cap high-growth stock; RARE is a small-cap high-growth stock; BEAM is a small-cap high-growth stock; IONS is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.